Randomized phase III study of gemcitabine versus TS-1 [S-1] versus gemcitabine plus TS-1 in unresectable advanced pancreatic cancer (with local progression or metastasis).

Trial Profile

Randomized phase III study of gemcitabine versus TS-1 [S-1] versus gemcitabine plus TS-1 in unresectable advanced pancreatic cancer (with local progression or metastasis).

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2015

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms GEST
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 29 Dec 2015 Results (subgroup analysis) published in the European Journal of Cancer (n = 261).
    • 18 Jan 2014 Pooled results for prognostic factors from GEST, GEMSAP, and JACCRO PC-01 presented at the 2014 Gastrointestinal Cancers Symposium.
    • 03 Apr 2013 Results have been published in the online version of the Journal of Clinical Oncology according to a Taiho Pharmaceutical media release. Results were also summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top